Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes

Overview of attention for article published in New England Journal of Medicine, June 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 167 news outlets
blogs: 13 blogs
twitter: 619 X users
facebook: 4 Facebook pages
wikipedia: 3 Wikipedia pages

reddit: 25 Redditors
video: 4 YouTube creators
bluesky: 606 Bluesky users
podcasts: 5 podcasts

Readers on

mendeley: 245 Mendeley

So far, Altmetric has seen 632 Bluesky posts from 606 Bluesky users, with an upper bound of 1,967,740 followers.

Doug Melton is an impressive guy. https://bsky.app/profile/did:plc:wtwpcoi6otsxpnh4xjlcprrg/post/3lslwevzvxs2n

RP @nejm.org: New in the September 4, 2025, issue of NEJM: Maridebart Cafraglutide for the Treatment of Obesity (MariTide phase 2 trial) nej.md/3ZHxLeb Stem Cell–Derived Islets for Type 1 Diabetes (VX-880-101 FORWARD phase 1–2 study) nej.md/3ZGupbv

RP @jmwallach.bsky.social: Another method but larger n from this year www.nejm.org/doi/full/10....

Another method but larger n from this year www.nejm.org/doi/full/10....

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity, including 628 additional Bluesky posts.